ADSORBED DIPHTHERIA VACCINE Injection

What is ADSORBED DIPHTHERIA VACCINE

ADSORBED DIPHTHERIA VACCINE is a sterile preparation of purified diphtheria toxoid—the inactivated exotoxin of Corynebacterium diphtheriae—adsorbed onto an aluminum-based adjuvant (usually aluminum hydroxide or aluminum phosphate). Adsorption improves antigen stability and prolongs residence time at the injection site, thereby enhancing the magnitude and durability of the humoral immune response. The vaccine is supplied as a single-dose 0.5 mL ampoule intended for intramuscular injection and contains no live organisms; hence it cannot cause diphtheria. Although routinely administered as part of combined formulations (DTaP, DT, Td, or Tdap), a monovalent adsorbed preparation remains valuable for booster immunizations or situations where the tetanus or pertussis components are contraindicated or undesired. Public-health authorities worldwide list diphtheria vaccination as essential because the illness can progress rapidly to airway obstruction, myocarditis, and neuritis, with case-fatality rates of 5-10 % even in modern intensive-care settings. Vaccination not only protects the individual but also reduces community carriage of toxigenic strains, contributing to herd immunity and interruption of outbreaks, particularly in displaced or undervaccinated populations. Each 0.5 mL dose typically contains ≥30 IU of diphtheria toxoid, trace residual formaldehyde (<0.02 %), and ≤0.85 mg elemental aluminum; it is preservative-free unless stated otherwise. The formulation meets the specifications of the WHO Technical Report Series and Pharmacopeial monographs (USP, Ph. Eur.).

• Type: Inactivated bacterial toxoid vaccine (adsorbed).
• Indications: Active immunization of infants, children, adolescents, and adults against diphtheria; booster dosing in occupational or travel settings; outbreak control.
• Presentation: 0.5 mL single-dose ampoule or vial; may also be supplied in combination products.
• Adjuvant: Aluminum salts to potentiate immune response.
• Immunogenicity: ≥95 % seroprotection after completion of primary series.
• Regulatory status: Included on WHO Model List of Essential Medicines; licensed in most jurisdictions.
• Target pathogens: Toxigenic strains of C. diphtheriae; antibodies neutralize circulating exotoxin.
• Clinical relevance: Prevents the severe systemic complications of diphtheria and reduces nasopharyngeal carriage.

How to use ADSORBED DIPHTHERIA VACCINE

Administration must follow national immunization guidelines and manufacturer instructions. The vaccine is given only by trained healthcare professionals using aseptic technique.

• Route & site: Deep intramuscular injection—anterolateral thigh (infants <12 months) or deltoid muscle (children ≥12 months, adolescents, adults). Avoid intravascular, intradermal, or gluteal administration to reduce nerve-injury and variable absorption risks.
• Dose & schedule: 0.5 mL per injection. Primary series at 2, 4, and 6 months of age; first booster at 15–18 months; second booster at 4–6 years. Adolescents and adults require a booster every 10 years. Unvaccinated individuals ≥7 years receive 3 doses (0, 1, and 6 months) followed by 10-yearly boosters.
• Co-administration: May be given concomitantly with other inactivated or live vaccines (e.g., polio, hepatitis B, pneumococcal) at separate anatomical sites using different syringes.
• Preparation: Inspect visually for particulate matter or discoloration. Shake gently to resuspend adsorbed toxoid; a homogeneous white suspension is acceptable.
• Technique: Use a 23–25 G needle (25 mm length in adults, 16 mm in infants). Clean skin with 70 % isopropyl alcohol and allow to dry. Aspirating is not required.
• Observation: Monitor recipients for ≥15 minutes post-injection to manage immediate hypersensitivity.
• Missed doses: Do not restart the series. Administer the overdue dose as soon as feasible, maintaining recommended minimum intervals.
• Documentation: Record trade name, lot number, expiry date, dose, site, and date in the patient’s immunization record.

The vaccine should never be administered intravenously, and strict adherence to cold-chain maintenance from storage through delivery is essential to preserve potency.

Mode of Action ADSORBED DIPHTHERIA VACCINE

The vaccine exploits adaptive immunity to generate durable, toxin-neutralizing antibodies. The key immunological events are as follows:

• Antigen presentation: After intramuscular injection, the aluminum adjuvant forms a depot that slowly releases diphtheria toxoid, facilitating uptake by resident dendritic cells and macrophages.
• MHC II processing: Antigen-presenting cells process the toxoid into peptides and display them on MHC II molecules, migrating to regional lymph nodes.
• T-helper activation: Naïve CD4⁺ T cells recognizing the toxoid peptide-MHC II complex differentiate into Th2 and follicular helper subsets, secreting IL-4, IL-5, and IL-21.
• B-cell priming: B cells with membrane-bound immunoglobulin specific for diphtheria toxin receive dual signals (antigen binding and CD40L–CD40 interaction) and proliferate in germinal centers.
• Affinity maturation: Somatic hypermutation and class-switch recombination yield high-affinity IgG1 and IgG3 antibodies directed at the toxin’s catalytic and receptor-binding domains.
• Memory formation: Long-lived plasma cells home to bone marrow, maintaining antibody titers for years, while memory B and T cells ensure rapid recall responses upon re-exposure.
• Toxin neutralization: Circulating antibodies bind diphtheria exotoxin, blocking its receptor-mediated endocytosis and subsequent ADP-ribosylation of elongation-factor 2, thereby preventing protein-synthesis inhibition and cell death.
• Herd immunity: Widespread immunity diminishes bacterial carriage and toxin production, indirectly protecting under-immunized individuals.

This multistep process typically achieves ≥0.1 IU/mL antitoxin concentration—the WHO-defined correlate of protection—within 4 weeks of the second primary dose. Booster doses reengage memory cells, rapidly amplifying antibody levels above 1.0 IU/mL, which confers long-term clinical protection.

ADSORBED DIPHTHERIA VACCINE Interactions ADSORBED DIPHTHERIA VACCINE

While the diphtheria toxoid component itself does not undergo pharmacokinetic interactions, several pharmacodynamic or immunological factors can modify vaccine response or safety:

• Immunosuppressive therapies: High-dose systemic corticosteroids (≥20 mg/day prednisone equivalent >14 days), calcineurin inhibitors, antimetabolites (azathioprine, mycophenolate), or biologics (TNF-α blockers, anti-CD20 antibodies) may blunt antibody formation. Defer routine vaccination until immune function recovers if possible.
• Cytotoxic chemotherapy & radiotherapy: Marked lymphopenia reduces seroconversion rates. Administer vaccine ≥2 weeks before initiating therapy or ≥3 months after completion, guided by oncologist advice.
• HIV infection: Non-suppressed viral load or CD4 <200 cells/μL may lead to suboptimal titers. Additional booster doses and post-vaccination serology can be considered.
• Plasma-derived immunoglobulins or antitoxin: Although interference is limited for toxoid vaccines, passive antibodies could slightly lower immunogenicity; revaccinate after a 3-month interval if high antitoxin doses were given for post-exposure prophylaxis.
• Live vaccines: No interference when co-administered at different sites; however, if not simultaneous, follow a 4-week separation from another live parenteral vaccine to avoid confounding adverse-event assessment.
• Antipyretics: Prophylactic high-dose acetaminophen or ibuprofen may marginally reduce antibody titers; reserve for symptomatic relief rather than routine pre-dosing.
• Laboratory assays: Recent vaccination can yield transient false-positive diphtheria serology; interpret results accordingly.
• Allergenic excipients: Trace formaldehyde, aluminum, or latex (in vial stoppers) may provoke reactions in sensitized individuals; verify product components.

Clinicians should review the comprehensive vaccination history and concomitant medications to optimize scheduling and maximize immunogenicity.

Dosage of ADSORBED DIPHTHERIA VACCINE

The standard dose across all age groups is 0.5 mL administered intramuscularly. Scheduling differs by age and immune status:

• Infants (Routine): Three-dose primary series at 2, 4, and 6 months; boosters at 15–18 months and 4–6 years (often as DTaP or DT).
• Children ≥7 years (Catch-up): If previously unvaccinated, give 0, 1, and 6 months. For partially vaccinated children, complete remaining doses ensuring ≥4 weeks between primary doses and ≥6 months before first booster.
• Adolescents & Adults: Single 0.5 mL booster every 10 years (commonly as Tdap/Td), or 5-year interval for tetanus-prone wound management.
• Pregnancy: One Tdap dose between 27–36 weeks gestation to confer passive antibody to the neonate; the diphtheria toxoid component is identical.
• Immunocompromised hosts: Follow standard schedule but verify post-series antitoxin titers and provide additional doses if <0.1 IU/mL.
• Post-exposure outbreak control: Administer a booster if ≥5 years since last dose, regardless of age.
• Administration notes:
  • Do not exceed 0.5 mL per injection.
  • Separate concomitant vaccines by ≥2.5 cm.
  • Observe 15 minutes post-injection.
• Missed appointments: Resume series without restarting; maintain minimum intervals (4 weeks primary, 6 months booster).

Always consult national immunization schedules, as interval recommendations may vary slightly between jurisdictions.

Possible side effects of ADSORBED DIPHTHERIA VACCINE

The vaccine is generally well-tolerated; most reactions are mild and self-limiting within 48 hours.

• Very common (≥10 %): Local pain, erythema, induration ≤5 cm; transient irritability or drowsiness in infants.
• Common (1–10 %): Low-grade fever (<38.5 °C), headache, malaise, myalgia, localized swelling >5 cm (sometimes called “Arthus-type reaction” after multiple boosters).
• Uncommon (0.1–1 %): Febrile seizures in infants predisposed to convulsions; rash or urticaria; vomiting.
• Rare (≤0.1 %): Hypersensitivity reactions including generalized urticaria, bronchospasm, or angio-oedema emerging within minutes to hours.
• Very rare (<1/10⁵): Anaphylaxis, Guillain-Barré syndrome, brachial neuritis, encephalomyelitis. Causal link remains unproven but is monitored via vaccine-adverse-event reporting systems.
• Injection site nodules: Small, painless subcutaneous granulomas may persist for weeks; usually related to aluminum adjuvant and resolve spontaneously.
• Syncope: Immediate vasovagal fainting in adolescents/young adults; mitigate by seated administration and observation.
• Management: Antipyretics for fever/myalgia; cold compress for local swelling; immediate epinephrine (0.01 mg/kg IM) for anaphylaxis.

Healthcare providers should counsel recipients about expected reactions, document any serious events, and report them to national pharmacovigilance programs.

ADSORBED DIPHTHERIA VACCINE Contraindications ADSORBED DIPHTHERIA VACCINE

Vaccination should be deferred or avoided under the following circumstances:

• Absolute contraindications
  • History of anaphylaxis or severe hypersensitivity to a previous dose of diphtheria-containing vaccine or to any component (e.g., aluminum, formaldehyde, trace antibiotics, latex in vial stopper).
  • Documented anaphylactic reaction to diphtheria toxoid.
• Relative contraindications / Precautions
  • Moderate or severe acute febrile illness (≥38.5 °C); postpone until recovery.
  • Progressive or unstable neurological disorders (e.g., uncontrolled epilepsy, infantile spasms) until condition stabilizes.
  • Arthus-type hypersensitivity after a previous diphtheria or tetanus toxoid-containing vaccine; delay boosters for ≥10 years.
  • Previous Guillain-Barré syndrome within 6 weeks of tetanus/diphtheria vaccination—evaluate risk–benefit.
  • Thrombocytopenia or bleeding disorders; use 25 mm fine-gauge needle and apply firm pressure without rubbing.
  • Pregnancy first trimester: not contraindicated but elective vaccination usually deferred to second/third trimester unless rapid protection is required.

Minor illnesses (mild URTI, low-grade fever, diarrhea) are not reasons to withhold the vaccine. If uncertainty exists, seek specialist advice.

Storage of ADSORBED DIPHTHERIA VACCINE

Potency is highly temperature-sensitive; robust cold-chain management is mandatory from manufacturer to point of use.

• Temperature: Store continuously at 2–8 °C (36–46 °F). Excursions outside this range accelerate toxoid degradation.
• Freezing: Do NOT freeze. Ice crystals irreversibly aggregate the aluminum-protein complex, markedly reducing immunogenicity. Discard if frozen.
• Light protection: Keep in original secondary packaging to shield from UV light, which can denature protein antigens.
• Handling: Transport in validated insulated containers with temperature monitors/loggers. Minimize fridge door openings.
• Inspection: Prior to administration, verify absence of clumps that do not resuspend, particulate contamination, or discoloration (yellow-brown tinge); discard if abnormal.
• Shelf life: Typically 24–36 months from manufacture when stored correctly; check expiry on ampoule/vial and outer carton.
• Open-vial policy: Single-dose ampoules must be discarded immediately after puncture. Unused doses from multi-dose vials may be kept for up to 6 hours at 2–8 °C if strict asepsis and WHO-EPI guidelines are met.
• Disposal: Expired or compromised vaccines are biological hazardous waste; incinerate or autoclave per local regulations.

Routine twice-daily temperature documentation and alarmed refrigeration units are recommended in healthcare facilities to maintain vaccine efficacy and compliance with Good Storage Practice.